Laboratory-scale sterilization device made of the same materials as large-capacity capsule filters and cartridge filters.
The "Scale-Up Acrodisc Syringe Filter" is a laboratory-scale sterilization device made from the same materials as large-capacity capsule filters and cartridge filters. It includes options suitable for filtering solutions that require low protein adsorption characteristics, such as "Supor (PES)," which offers high flow rates and throughput performance, and "Fluorodyne II," which is suitable for applications that require PVDF membranes. It is ideal for small-volume sterilizing filtration, determining product compatibility and recovery, and conducting preliminary filtration performance tests. 【Product Lineup】 ■Supor ■Supor EKV ■Fluorodyne II ■Ultrapore ■Posidyne *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Other Features】 ■Supor - Membrane characterized by high flow rate and high processing capacity - Suitable for filtration of solutions that require low protein adsorption properties - Not suitable for certain ketones ■Supor EKV - Supor membrane with an asymmetric structure enabled by Mach V technology - Exhibits high flow rate and throughput performance ■Fluorodyne II - Membrane characterized by high flow rate - Suitable for applications that require PVDF membranes - Not suitable for certain ethers ■Ultrapore - Provides resistance to a wide range of solvents and chemicals, along with low extractable levels ■Posidyne - Membrane enhanced for the removal of bioburden and pyrogens in aqueous solutions *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Application】 ■ Small volume sterilizing filtration ■ Determination of product compatibility and recoverability ■ Preliminary filtration performance testing *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.